Your browser doesn't support javascript.
loading
Efficacy Analysis of Unrelated Cord Blood Transplantation for High-Risk Refractory AML1-ETO Positive Myeloid Leukemia / 中国实验血液学杂志
Journal of Experimental Hematology ; (6): 1246-1252, 2019.
Artigo em Chinês | WPRIM | ID: wpr-775733
ABSTRACT
OBJECTIVE@#To analyze the clinical outcomes of engraftment, graft-versus-host disease (GVHD) and survival in the patients with AML1-ETO positive acute myeloid leukemia (AML) treated with unrelated umbilical cord blood transplantation (UCBT).@*METHODS@#Forty-Five patients with high-risk refractory AML1-ETO positive AML were treated with a single UCBT in a single center from July 2010 to April 2018. All the patients underwent a myeloablative preconditioning regimen,and cyclosporine A (CSA) combined with mycophenolate mofetil (MMF) was used to prevent GVHD.@*RESULTS@#The median value of total nucleated cells (TNC) in cord blood was 5.21 (1.96-12.68)×10/kg recipient body weight, and that of CD34+ cells was 5.61 (0.56-15.4)×10/kg recipient weight. The implantation rate of neutrophil at 42 d and that of platelet at 120 d were 95.6% and 86.7%, respectively. The median time of absolute neutrophil count (ANC)>0.5×10/L and platelet 20×10/L were 16 (12-18) d and 37 (17-140) d after transplantation, respectively. The cumulative incidence of Ⅰ -Ⅳ grade acute GVHD (aGVHD) at 100 d after transplantation was 48.9% (95% CI 33.5%-62.6%), Ⅱ-Ⅳ grade aGVHD occurred in 12 cases (33.3%) (95% CI 20%-47.2%) , and Ⅲ-Ⅳ grade a GVHD in 8 cases (20%) (95% CI 9.8% -32.8%). In 5 cases of 40 patients survived over 100 days, the chronic GVHD (cGVHD) occurred after transplantation, among which 4 were localized, and 1 was extensive. 3 patients relapsed, and the 2-year cumulative relapse rate was 9.5% (95% CI 2.4%-22.8%). The median follow-up time was 23.5 (0.9-89.67) months, 10 patients died, 2-year disease-free survival rate (DFS) was 72.7%, and overall survival rate (OS) was 75.5%. Multivariate analysis showed that Ⅲ-Ⅳ. acute GVHD (aGVHD) affected overall survival.@*CONCLUSION@#UCBT is an effective rescue treatment for patients with high-risk refractory AML1-ETO positive AML.
Assuntos
Texto completo: DisponíveL Índice: WPRIM (Pacífico Ocidental) Assunto principal: Leucemia Mieloide Aguda / Proteínas de Fusão Oncogênica / Condicionamento Pré-Transplante / Transplante de Células-Tronco de Sangue do Cordão Umbilical / Transplante de Células-Tronco de Sangue Periférico / Subunidade alfa 2 de Fator de Ligação ao Core / Proteína 1 Parceira de Translocação de RUNX1 / Doença Enxerto-Hospedeiro / Ácido Micofenólico Tipo de estudo: Estudo de etiologia Limite: Humanos Idioma: Chinês Revista: Journal of Experimental Hematology Ano de publicação: 2019 Tipo de documento: Artigo

Similares

MEDLINE

...
LILACS

LIS

Texto completo: DisponíveL Índice: WPRIM (Pacífico Ocidental) Assunto principal: Leucemia Mieloide Aguda / Proteínas de Fusão Oncogênica / Condicionamento Pré-Transplante / Transplante de Células-Tronco de Sangue do Cordão Umbilical / Transplante de Células-Tronco de Sangue Periférico / Subunidade alfa 2 de Fator de Ligação ao Core / Proteína 1 Parceira de Translocação de RUNX1 / Doença Enxerto-Hospedeiro / Ácido Micofenólico Tipo de estudo: Estudo de etiologia Limite: Humanos Idioma: Chinês Revista: Journal of Experimental Hematology Ano de publicação: 2019 Tipo de documento: Artigo